Current medical research and opinion
-
During the COVID-19 pandemic, Americans have increasingly relied on internet versus television news. The extent to which this change in health news consumption practice impacts health knowledge is not known. This study investigates the relationship between most trusted information source and COVID-19 knowledge. ⋯ COVID-19 knowledge correlates with trusted news source. To increase public knowledge of COVID-19 in order to maximize information dissemination and compliance with COVID-19-related public health recommendations, those who provide health information should consider use of the public's most trusted sources of information, as well as monitoring and correcting misinformation presented by other sources. Independent content review for accuracy in media may be warranted in public health emergencies to improve knowledge.
-
Randomized Controlled Trial
Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain.
To evaluate the efficacy of lasmiditan (LTN) in treating migraine attacks of mild vs. moderate or severe pain intensity. ⋯ Data from two placebo-controlled, single-attack trials, and an open-label study including treatment of multiple attacks, suggested a tendency to relatively better efficacy outcomes when LTN treatment was initiated at mild vs. moderate to severe pain. Further research is needed to better understand the relationship of lasmiditan outcomes to the time of administration in the course of a migraine attack.
-
Assess the real-world efficacy of netarsudil, either as monotherapy or concomitant therapy, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) requiring modification of intraocular pressure (IOP)-lowering treatment. ⋯ In the real-world treatment of patients with OAG or OHT, netarsudil consistently maintained IOP control when it replaced previous IOP-lowering therapies and provided additional IOP-lowering efficacy when added to other treatments.
-
Burosumab is an orphan medicinal product (OMP) approved in Europe for the treatment of X-linked hypophosphatemia (XLH). The aim of this study was to assess the value of burosumab versus conventional therapy for the treatment of paediatric XLH, through a multi-criteria decision analysis (MCDA) framework for health technology assessment (HTA) of OMPs in Portugal. ⋯ MCDA represents a powerful tool in HTA decision-making for OMPs. The results of this MCDA acknowledge burosumab as a disease-modifying drug, deemed superior to conventional therapy for the treatment of paediatric XLH.
-
Fast dissemination of research is important for improving treatments and thus benefitting patients, caregivers, and researchers. However, getting scientific papers published may take a long time. The editorial handling time can be delayed by several processes both before and after acceptance of the paper. The aim of this study was to systematically review the editorial handling time of biomedical peer-reviewed literature (i.e. time from submission to publication). ⋯ Editorial handling times of journals varied widely from a few months to almost two years, which delays the availability of new evidence. The editorial handling time did not differ between submission-to-acceptance-time and acceptance-to-publication-time. Examining differences in editorial processes between journals with long and short editorial handling times may help uncover, which processes are frequent causes of delay and thereby where to improve.